The gene therapies for cancer treatment market size was valued at US$ 11.59 billion in 2025 and is projected to grow to 16.22 billion in 2026. Forecasts suggest it will reach approximately US$ 238.77 ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

The malignant pediatric brain tumor medulloblastoma is driven by proteins deep within the cancer cells, for which there are ...

Rice University bioengineers have demonstrated a nonsurgical way to quiet a seizure-relevant brain circuit in an animal model ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that ...

Through studies that were amongst the largest of their kind, we identified several genes involved in breast and/or ovarian cancer predisposition such as CHEK2, BRIP1, ATM, PALB2, RAD51C and RAD51D.

The global TCR therapy market size is calculated at USD 410.6 million in 2025 and is expected to reach around USD 1264.73 million by 2034, growing at a CAGR of 13.44% for the forecasted period.Ottawa, ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...

A study harnessing a successful treatment for lymphoma and applying it to other cancers promises a breakthrough in how to attack a range of tumours using the body’s own immune system.

Cambridge, MA - Traditional bisulfite sequencing damages DNA, while enzyme-based alternatives are inconsistent. A novel methylation analysis method ...

Miguel Forte, current President of the International Society for Cell & Gene Therapy (ISCT), joins Blue Cell as a Non-Executive Director Highly ...

The malignant pediatric brain tumor medulloblastoma is driven by proteins deep within the cancer cells, for which there are often no effective drugs available.